CMS's 'Cost-Cutting' Rule Hits Seniors: More Than Just Drug Prices
While the mainstream media cheers Medicare Advantage windfalls, a new CMS proposal quietly shifts costs and access for older Americans.
The direct answer
The Centers for Medicare & Medicaid Services (CMS) has proposed significant changes for 2027 that could impact seniors, though the initial coverage often focuses on industry gains. The agency plans to drastically cut payments for drugs acquired under the 340B program, proposing to pay 33.4% below the Average Sales Price (ASP)
"Taking the survey's results into account to more accurately align Medicare payments with hospital drug acquisition costs, we are proposing for CY 2027 to pay for 340B acquired drugs at the drug's Average Sales Price (ASP) minus 33.4%."
. This move, framed by CMS as aligning payments with acquisition costs
"“This proposed rule focuses squarely on patient affordability by strengthening our utilization management tools, aligning drug payments with actual acquisition costs, and removing site-of-care disparities that have unnecessarily driven up costs for millions of seniors,” CMS Administrator Dr. Mehmet Oz said in a Thursday press release."
, could reduce the financial lifeline for safety-net hospitals that serve many seniors. Concurrently, CMS is expanding site-neutral policies for outpatient services, meaning certain services performed in hospital outpatient departments will be reimbursed at lower rates, similar to those paid to physician offices. This, too, is presented as a cost-saving measure, but it may lead to higher out-of-pocket costs for seniors receiving common imaging or diagnostic services at hospital facilities
"“This proposed rule focuses squarely on patient affordability by strengthening our utilization management tools, aligning drug payments with actual acquisition costs, and removing site-of-care disparities that have unnecessarily driven up costs for millions of seniors,” CMS Administrator Dr. Mehmet Oz said in a Thursday press release."
. While Medicare Advantage plans are set to receive a substantial rate increase for 2027, potentially adding over $13 billion to their coffers
CMS finalized its 2027 Medicare Advantage and Part D payment policies, projecting a net average 2.48% increase, or more than $13B in additional MA payments. The agency will also keep the 2024 MA risk adjustment model and exclude most unlinked chart review diagnoses from risk…
— Wall St Engine link
, these proposed cuts and policy shifts could offset those gains for beneficiaries by altering drug access and service costs.
The 340B Program: A Lifeline Under Threat
CMS is proposing to slash reimbursement rates for drugs purchased through the 340B program, a federal initiative designed to help safety-net providers purchase outpatient drugs at a discount
"Taking the survey's results into account to more accurately align Medicare payments with hospital drug acquisition costs, we are proposing for CY 2027 to pay for 340B acquired drugs at the drug's Average Sales Price (ASP) minus 33.4%."
. The proposed rule suggests paying 33.4% below the Average Sales Price (ASP) for these drugs, a significant reduction from current rates
"Taking the survey's results into account to more accurately align Medicare payments with hospital drug acquisition costs, we are proposing for CY 2027 to pay for 340B acquired drugs at the drug's Average Sales Price (ASP) minus 33.4%."
. This policy, which CMS Administrator Dr. Mehmet Oz claims aligns payments with acquisition costs
"“This proposed rule focuses squarely on patient affordability by strengthening our utilization management tools, aligning drug payments with actual acquisition costs, and removing site-of-care disparities that have unnecessarily driven up costs for millions of seniors,” CMS Administrator Dr. Mehmet Oz said in a Thursday press release."
and is a move to "more accurately align Medicare payments with hospital drug acquisition costs"
"Taking the survey's results into account to more accurately align Medicare payments with hospital drug acquisition costs, we are proposing for CY 2027 to pay for 340B acquired drugs at the drug's Average Sales Price (ASP) minus 33.4%."
, could severely impact the financial viability of hospitals that serve low-income and vulnerable populations, including many seniors. The reduction in savings could force these hospitals to cut services or increase prices elsewhere, ultimately affecting patient access to care and affordable medications. This move directly challenges the system that provides crucial discounts for essential drugs
"First, CMS is proposing to pay hospitals significantly less for medications acquired under the 340B drug discount program."
.
Site-Neutral Policies: Shifting Costs to Patients
The proposed rule also expands site-neutral policies, meaning that certain services, like common imaging and diagnostic tests, will be reimbursed at lower rates if performed in a hospital outpatient department compared to a freestanding facility. CMS frames this as removing "site-of-care disparities that have unnecessarily driven up costs"
"“This proposed rule focuses squarely on patient affordability by strengthening our utilization management tools, aligning drug payments with actual acquisition costs, and removing site-of-care disparities that have unnecessarily driven up costs for millions of seniors,” CMS Administrator Dr. Mehmet Oz said in a Thursday press release."
. However, for seniors, this often translates to higher out-of-pocket expenses. While Medicare may pay less to the hospital, the patient's coinsurance or deductible, often a percentage of the Medicare payment, could increase. This policy shift, coupled with the 340B cuts, creates a double whammy: potentially reduced access to discounted drugs and higher direct costs for routine healthcare services that seniors frequently utilize.
The Medicare Advantage Windfall: A Distraction?
While the CMS proposed rule for 2027 contains these potentially detrimental changes for beneficiaries, the headlines have been dominated by a substantial increase in Medicare Advantage (MA) payments. CMS finalized payment policies projecting a net average 2.48% increase for 2027, translating to over $13 billion in additional payments for MA plans
CMS finalized its 2027 Medicare Advantage and Part D payment policies, projecting a net average 2.48% increase, or more than $13B in additional MA payments. The agency will also keep the 2024 MA risk adjustment model and exclude most unlinked chart review diagnoses from risk…
— Wall St Engine link
. This has sent stocks of major MA players like UnitedHealth Group ($UNH) surging [c2, c1]. The Trump administration's finalization of the Star Ratings overhaul also contributed to this "massive cash injection" for insurers
Medicare Advantage just got a massive cash injection 💰 Trump admin finalizes Star Ratings overhaul — $18B in extra payments flowing to health insurers. This is a direct tailwind for the big MA players: $UNH , $HUM , $CVS , $ELV , $CNC all stand to benefit from higher reimbursement…
— Casey | Trade Tracs link
. This significant financial boost for health plans, while framed as a positive development, could be seen as a distraction from the proposed cuts that may disproportionately affect the very seniors these plans are meant to serve, potentially leading to higher out-of-pocket costs and reduced access to critical drug discounts
Everything you need to know about the CMS news, and what it means for $UNH and $OSCR : $UNH surged after CMS finalized a much better-than-expected Medicare Advantage rate update for 2027. The headline rate came in at +2.48%, far above the +1.0% many were bracing for, and CMS…
— Stocker-Man link
.
Common mistakes
- Focusing solely on the Medicare Advantage payment increase without detailing the downstream effects on beneficiaries.
The mainstream narrative often highlights the financial gains for insurers, overlooking how policy changes can shift costs and impact patient access to care and affordable medications, especially for seniors. - Presenting CMS's claims about 'patient affordability' and 'cost alignment' at face value without critical analysis.
These terms are often industry-speak for cost-shifting or reduced reimbursements that can negatively affect patient access and out-of-pocket expenses, particularly for vulnerable populations. - Failing to connect the 340B cuts and site-neutral expansion to the specific financial burden on seniors.
While these are complex policy changes, their real-world impact is on who pays for healthcare. The current framing often obscures the potential for increased out-of-pocket costs for older Americans.
CMS finalized its 2027 Medicare Advantage and Part D payment policies, projecting a net average 2.48% increase, or more than $13B in additional MA payments. The agency will also keep the 2024 MA risk adjustment model and exclude most unlinked chart review diagnoses from risk…
— Wall St Engine link
, CMS's proposed 2027 payment rule is quietly poised to shift costs onto seniors. The drastic proposed cut to 340B drug payments, paying ASP minus 33.4%
"Taking the survey's results into account to more accurately align Medicare payments with hospital drug acquisition costs, we are proposing for CY 2027 to pay for 340B acquired drugs at the drug's Average Sales Price (ASP) minus 33.4%."
, will strain the safety-net hospitals that many older Americans rely on for affordable medications. Furthermore, expanding site-neutral policies, which CMS Administrator Dr. Mehmet Oz claims will "focus squarely on patient affordability"
"“This proposed rule focuses squarely on patient affordability by strengthening our utilization management tools, aligning drug payments with actual acquisition costs, and removing site-of-care disparities that have unnecessarily driven up costs for millions of seniors,” CMS Administrator Dr. Mehmet Oz said in a Thursday press release."
, will likely increase out-of-pocket expenses for common procedures for seniors receiving care at hospital outpatient departments. This isn't about universal benefit; it's a complex financial maneuver that could leave seniors paying more for essential services.
Frequently asked
What is the 340B drug program and why is it important for seniors?
The 340B program allows certain safety-net hospitals and clinics to purchase outpatient prescription drugs at significantly reduced prices. This is crucial for seniors who rely on these providers for affordable medications, as the savings help these facilities offer lower costs and maintain essential services for vulnerable populations.
What are 'site-neutral' policies and how could they affect me?
Site-neutral policies aim to pay the same rate for a service regardless of where it's performed (e.g., a hospital outpatient department vs. a doctor's office). While CMS claims this cuts costs, it often means lower reimbursement for hospitals, which can lead to higher out-of-pocket co-pays and deductibles for patients, including seniors, for services like imaging and diagnostics.
If Medicare Advantage plans are getting more money, why might my costs increase?
The increased payments to Medicare Advantage plans are primarily for the plans themselves. CMS's proposed cuts to 340B drug reimbursements and expansion of site-neutral policies could directly increase the cost of drugs and services that seniors pay for out-of-pocket or through co-insurance, potentially negating any indirect benefits from the MA payment increase.
Sources
More from Healthcare Policy → · Back to Perch · Browse all stories